Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Pharmaceutical

Teva Targets US$6-7bn Innovative Medicines Sales by 2030

Sreepriya Prasannan
Sreepriya Prasannan

NewsWritten by our team from the primary sources linked below. Reviewed, verified and approved by a human editor. How we check

Speed:
Teva Targets US$6-7bn Innovative Medicines Sales by 2030

Teva Pharmaceutical Industries is targeting US$6 to 7 billion in innovative medicines revenue by 2030, the company said at its first R&D Day on 11 November 2026. That is above the "more than US$5 billion" franchise goal Teva set in May 2025. Teva also said it could launch one innovative medicine a year through 2030.

The update came in a company press release issued on the day of the event, which Teva webcast from New York. Teva did not break the 2030 target down by product, and it said the pipeline figures it gave are not risk-adjusted and depend on regulatory approvals.

Key Highlights:
  • New 2030 goal: US$6 to 7 billion in innovative medicines revenue, against a "more than US$5 billion" goal set at Teva's Innovation and Strategy Day on 29 May 2025.
  • Pipeline: ten innovative programs, including two clinical antibodies discovered in-house, and seven late-stage assets with combined peak sales potential above US$10 billion (not risk-adjusted).
  • Data: Teva's anti-IL-15 antibody TEV-'408 met its primary endpoint in a Phase 2a study in celiac disease; a Phase 2b study is expected to start in the second half of 2027.
  • Other 2030 targets: innovative gross margin above 75%, mid-single-digit total revenue growth from 2026 to 2030, and free cash flow above US$3.5 billion.
  • Ireland: Teva makes and develops respiratory products in Waterford and has made Sudocrem in Baldoyle, Dublin, since 1984, according to Teva's Irish website. The R&D Day release does not mention Ireland.

What did Teva announce at its R&D Day?

The headline is the higher revenue target for branded, innovative medicines. Teva said this revenue has more than doubled since it launched its Pivot to Growth strategy in 2023, and that innovative medicines now make up more than 20% of its revenue. It reported a gross margin of about 55% as of the third quarter of 2026.

Richard Francis, President and CEO, said: "With our Pivot to Growth strategy, we set out to transform Teva." Presenters also included Eric Hughes, Executive Vice President of Global R&D and Chief Medical Officer, Steffen Nock, Chief Scientific Officer, David Gardiner, Chris Fox and Chief Financial Officer Eli Kalif.

Teva's 2030 innovative medicines goal, then and now (Teva press releases)
AnnouncementInnovative medicines goal for 2030
Innovation and Strategy Day, 29 May 2025A franchise of more than US$5 billion
R&D Day, 11 November 2026US$6 to 7 billion in revenue
Split by productNot disclosed in the release

Which pipeline programs did Teva highlight?

Teva said its innovative pipeline has grown to ten programs. The most detailed update concerned its anti-IL-15 antibody, TEV-'408, which Teva is testing in three immune-mediated conditions.

Programs named in Teva's R&D Day release, 11 November 2026
ProgramStatus reported by Teva
Anti-IL-15 (TEV-'408), celiac diseasePhase 2a met its primary endpoint; Phase 2b expected to start in the second half of 2027
Anti-IL-15 (TEV-'408), vitiligoMoving into a seamless Phase 2/3 study, based on Phase 1b results
Anti-IL-15 (TEV-'408), alopeciaBeing evaluated; no phase given
ATTENUKINE (anti-PD-1/IL-2)Phase 1 in advanced cancer; early efficacy signals and a favourable safety profile so far
Anti-TSLP/IL-13Early stage, for potential asthma treatments
Anti-TL1A/IL-23Early stage, for potential inflammatory bowel disease treatments
EcopipamFDA priority review

Teva did not publish the size of the celiac effect or the number of patients in the release, so the strength of that result cannot yet be judged. Readers can follow active studies in these conditions on our celiac disease and vitiligo trial pages, and Teva-sponsored studies on our Teva R&D sponsor page.

Where do WELTRUZA and ecopipam stand?

The R&D Day release says Teva has "recently launched" WELTRUZA (olanzapine). Teva's third-quarter results release of 3 November 2026 gives more detail: the US Food and Drug Administration approved WELTRUZA in October 2026 as a once-monthly injection for schizophrenia, and the European Medicines Agency accepted Teva's marketing authorisation application in May 2026. The EU review is therefore still open, and no Irish launch date has been announced. Background on the molecule is on our olanzapine compound page.

The same quarterly release says the FDA accepted Teva's new drug application for ecopipam in paediatric Tourette syndrome, with an action date expected in the first quarter of 2027. Teva describes ecopipam as a potential first-in-class medicine that acts selectively on the dopamine D1 receptor; it came to Teva through its acquisition of Emalex. The quarterly release also reported that Teva stopped a Phase 2 study of emrusolmin in multiple system atrophy after an interim futility analysis.

What financial targets did Teva set?

Teva paired the revenue goal with margin and cash targets. Metrics other than revenue are non-GAAP, and Teva gave no GAAP reconciliation for its outlook.

Targets and past figures in Teva's R&D Day release
MeasureFigure
Innovative medicines revenue, 2030US$6 to 7 billion
Innovative gross margin, through 2030Above 75%
Total revenue growth, 2026 to 2030Mid-single digits
Free cash flow, 2030Above US$3.5 billion
Net debt to adjusted EBITDA, end of 20272.0x
Free cash flow generated, 2023 to 2025More than US$6 billion
Biosimilar revenue, 2024 to 2026Expected to double
Credit ratingReturned to investment grade in 2026

Teva also said its three main branded products, AUSTEDO, AJOVY and UZEDY, are expected to grow by more than about 125% by the end of 2026. AJOVY is the brand name of fremanezumab, covered on our fremanezumab drug page. In May 2025 Teva said it expected AUSTEDO sales alone to exceed US$2.5 billion in 2027.

What does Teva's plan mean for Ireland?

The R&D Day release does not mention Ireland, any Irish site, or any Irish trial. Teva's Irish operations are set out on its own Irish website, teva.ie. It lists the Swords, Dublin, team that keeps medicine supply moving in Ireland; the Waterford site, which manufactures and develops respiratory products mainly for the United States and about 30 other countries and has an on-site R&D centre for asthma and COPD products; the Baldoyle, Dublin, plant that has made Sudocrem since 1984; and a research site in Northern Ireland.

The same page says Teva employs around 650 people across two sites in the Republic of Ireland and that its Irish operations contributed €173 million directly to Irish GDP in 2023. Waterford is also listed on our Ireland pharma map. None of the new pipeline programs is linked to an Irish site in the sources we read, so any effect on Irish jobs or investment is not disclosed.

Frequently asked questions

What is Teva's innovative medicines revenue target for 2030?

US$6 to 7 billion, announced at the company's R&D Day on 11 November 2026. The earlier goal, set in May 2025, was a franchise of more than US$5 billion.

Which Teva drug had new clinical data at the R&D Day?

The anti-IL-15 antibody TEV-'408. Teva said a Phase 2a study in celiac disease met its primary endpoint, and that a Phase 2b study should start in the second half of 2027.

How many new medicines does Teva plan to launch?

Teva said it has the potential for one innovative medicine launch a year over the next five years, through 2030, subject to approvals.

Is WELTRUZA available in Ireland?

Not yet. The FDA approved it in October 2026, and the European Medicines Agency accepted the EU application in May 2026. No EU decision or Irish launch date has been announced.

Does Teva manufacture in Ireland?

Yes. Teva's Irish website says it makes respiratory products in Waterford and Sudocrem in Baldoyle, Dublin.

Outlook

The next dated milestones are the FDA decision on ecopipam, expected in the first quarter of 2027, the start of the vitiligo Phase 2/3 study, and the celiac Phase 2b study in the second half of 2027. Teva said the R&D Day webcast and presentation are on its investor relations website. Priya Life Science will report the EU decision on WELTRUZA and any Irish site investment linked to the new pipeline when Teva or the regulators publish them.

Sources

Cover image: Teva Canada building at 575 Hood Road, Markham, Ontario. It is not an Irish Teva site and not the R&D Day venue. Photo: Raysonho @ Open Grid Scheduler / Scalable Grid Engine, CC0 1.0 (public domain dedication), via Wikimedia Commons, cropped.

Reviewed for editorial accuracy by Sreepriya Prasannan, Founder & Editor MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany
Our standards
Related from our data
Austedo 24 mg prolonged-release tablets — Deutetrabenazine · Irish Medicines Database Olanzapine 10mg Film-coated Tablets — Olanzapine · Irish Medicines Database Olanzapine Accord 7.5 mg film-coated tablets — Olanzapine form 1 · Irish Medicines Database
The Effectiveness of the Twin Block and Carriere Motion Appliances in Post-pubertal Patients and an Evaluatio… — Active in Ireland · Trials Tracker
Drugs in this article: current clinical trials
Most-trialled drugs in our registers
Browse all trial registers →

Get the Friday brief

One email every Friday: a 60-second summary, then only the topics you choose: industry news, approvals and market access, shortages, Irish trials, careers or data, all built from public registers.

Free. Unsubscribe from any email with one click. See our privacy policy.

About the Author
Sreepriya Prasannan

Sreepriya Prasannan

Writer at Priya Life Science · Pharmaceutical

Sreepriya Prasannan is the Founder and Editor of Priya Life Science, Ireland's independent pharma, biotech and MedTech platform. She holds an MSc in Digital Transformation (Life Science) from Griffith College Dublin, with a background in QA, GMP and production operations. Shortlisted for STEM Graduate of the Year at the Business Post Women in STEM Awards 2026 and a Top 14 finalist in the HSE Spark Ignite 2026 innovation programme, she writes on regulatory trends, GMP compliance and careers across the Irish and European life sciences.

Discussion
No comments yet. Be the first to share your thoughts!
Leave a Comment